레드힐 바이오파마 (RDHL) 주가

레드힐 바이오파마(RDHL)는 NASDAQ에 상장된 Healthcare · Drug Manufacturers - Specialty & Generic 기업입니다. 현재가 $0.56 (-5.36%), 시가총액 $0.00B, 52주 최저~최고 $0.74 ~ $2.52.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Cro

핵심 지표

• 현재가: $0.56 (-5.36%)
• 시가총액: $0.00B
• 52주 최저~최고: $0.74 ~ $2.52
• 섹터: Healthcare
• 산업: Drug Manufacturers - Specialty & Generic
• 거래소: NASDAQ

레드힐 바이오파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

레드힐 바이오파마 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.23
• 순이익률: -1.50%
• 영업이익률: -27.65%

자주 묻는 질문